Dimed Distribuidora de Medicamentos Croissance future

Future contrôle des critères 4/6

Dimed Distribuidora de Medicamentos devrait augmenter ses bénéfices et son chiffre d'affaires de 23.4% et de 10.8% par an respectivement. Le BPA devrait croître de de 27% par an. Le rendement des capitaux propres devrait être 13.6% dans 3 ans.

Informations clés

23.4%

Taux de croissance des bénéfices

27.0%

Taux de croissance du BPA

Consumer Retailing croissance des bénéfices	29.9%
Taux de croissance des recettes	10.8%
Rendement futur des capitaux propres	13.6%
Couverture par les analystes	Low
Dernière mise à jour	14 Nov 2024

Mises à jour récentes de la croissance future

Dimed S.A. Distribuidora de Medicamentos Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected

Nov 17

Recent updates

Dimed S.A. Distribuidora de Medicamentos Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected

Nov 17

Investors Could Be Concerned With Dimed Distribuidora de Medicamentos' (BVMF:PNVL3) Returns On Capital

Nov 04

These 4 Measures Indicate That Dimed Distribuidora de Medicamentos (BVMF:PNVL3) Is Using Debt Extensively

Jul 12

Investors Shouldn't Be Too Comfortable With Dimed Distribuidora de Medicamentos' (BVMF:PNVL3) Robust Earnings

May 27

Be Wary Of Dimed Distribuidora de Medicamentos (BVMF:PNVL3) And Its Returns On Capital

Apr 15

Dimed Distribuidora de Medicamentos (BVMF:PNVL3) Seems To Use Debt Quite Sensibly

Mar 25

The Returns On Capital At Dimed Distribuidora de Medicamentos (BVMF:PNVL3) Don't Inspire Confidence

Jan 06

Dimed S.A. Distribuidora de Medicamentos' (BVMF:PNVL3) Stock Retreats 26% But Earnings Haven't Escaped The Attention Of Investors

Oct 23

Dimed Distribuidora de Medicamentos (BVMF:PNVL3) Is Reinvesting At Lower Rates Of Return

Aug 15

Prévisions de croissance des bénéfices et des revenus

BOVESPA:PNVL3 - Estimations futures des analystes et données financières antérieures (BRL Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	6,391	187	19	314	5
12/31/2025	5,702	145	-33	272	5
12/31/2024	5,151	122	6	322	2
9/30/2024	4,818	104	125	274	N/A
6/30/2024	4,712	91	190	321	N/A
3/31/2024	4,660	108	178	313	N/A
12/31/2023	4,461	93	157	297	N/A
9/30/2023	4,325	88	144	282	N/A
6/30/2023	4,211	83	175	325	N/A
3/31/2023	4,116	84	69	228	N/A
12/31/2022	3,990	86	24	205	N/A
9/30/2022	3,799	85	17	198	N/A
6/30/2022	3,584	83	21	189	N/A
3/31/2022	3,375	80	15	175	N/A
12/31/2021	3,225	79	-4	131	N/A
9/30/2021	3,135	79	-56	78	N/A
6/30/2021	3,032	79	-58	63	N/A
3/31/2021	2,878	62	-41	57	N/A
12/31/2020	2,819	56	46	131	N/A
9/30/2020	2,764	56	82	147	N/A
6/30/2020	2,754	62	34	90	N/A
3/31/2020	2,780	78	73	133	N/A
12/31/2019	2,725	77	75	129	N/A
9/30/2019	2,638	80	89	131	N/A
6/30/2019	2,562	79	65	106	N/A
3/31/2019	2,500	76	72	117	N/A
12/31/2018	2,432	75	51	110	N/A
9/30/2018	2,359	65	-20	45	N/A
6/30/2018	2,317	59	N/A	62	N/A
3/31/2018	2,282	59	N/A	29	N/A
12/31/2017	2,258	60	N/A	41	N/A
9/30/2017	2,238	60	N/A	78	N/A
6/30/2017	2,191	59	N/A	68	N/A
3/31/2017	2,146	57	N/A	104	N/A
12/31/2016	2,129	53	N/A	102	N/A
9/30/2016	2,095	53	N/A	92	N/A
6/30/2016	2,074	50	N/A	93	N/A
3/31/2016	2,043	50	N/A	76	N/A
12/31/2015	1,986	45	N/A	73	N/A
9/30/2015	1,963	44	N/A	59	N/A
6/30/2015	1,927	43	N/A	56	N/A
3/31/2015	1,916	48	N/A	26	N/A
12/31/2014	1,887	49	N/A	23	N/A
9/30/2014	1,835	50	N/A	29	N/A
6/30/2014	1,823	58	N/A	50	N/A
3/31/2014	1,786	55	N/A	66	N/A
12/31/2013	1,740	56	N/A	62	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de PNVL3 ( 23.4% par an) est supérieure au taux d'épargne ( 10.4% ).

Bénéfices vs marché: Les bénéfices de PNVL3 ( 23.4% par an) devraient croître plus rapidement que le marché BR ( 12.6% par an).

Croissance élevée des bénéfices: Les bénéfices de PNVL3 devraient augmenter de manière significative au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de PNVL3 ( 10.8% par an) devrait croître plus rapidement que le marché BR ( 7.4% par an).

Croissance élevée des revenus: Le chiffre d'affaires de PNVL3 ( 10.8% par an) devrait croître plus lentement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Le retour sur capitaux propres de PNVL3 devrait être faible dans 3 ans ( 13.6 %).

Dimed Distribuidora de Medicamentos Croissance future

Future contrôle des critères 4/6

Informations clés

Mises à jour récentes de la croissance future

Dimed S.A. Distribuidora de Medicamentos Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected

Consensus EPS estimates fall by 30%

Price target decreased by 16% to R$14.38

Price target decreased by 8.5% to R$16.13

Price target decreased by 8.8% to R$17.65

Price target decreased by 9.1% to R$18.72

Recent updates

Dimed S.A. Distribuidora de Medicamentos Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected

Third quarter 2024 earnings released: EPS: R$0.24 (vs R$0.16 in 3Q 2023)

Second quarter 2024 earnings released: EPS: R$0.034 (vs R$0.15 in 2Q 2023)

Consensus EPS estimates fall by 30%

Price target decreased by 16% to R$14.38

Price target decreased by 8.5% to R$16.13

First quarter 2024 earnings released: EPS: R$0.23 (vs R$0.12 in 1Q 2023)

Full year 2023 earnings: Revenues in line with analyst expectations

Upcoming dividend of R$0.068 per share at 1.9% yield

Third quarter 2023 earnings released: EPS: R$0.16 (vs R$0.12 in 3Q 2022)

Upcoming dividend of R$0.046 per share at 1.6% yield

Second quarter 2023 earnings released: EPS: R$0.15 (vs R$0.16 in 2Q 2022)

Price target decreased by 8.8% to R$17.65

Price target decreased by 9.1% to R$18.72

Full year 2022 earnings released: EPS: R$0.58 (vs R$0.53 in FY 2021)

No independent directors

Third quarter 2022 earnings released

Investor sentiment deteriorated over the past week

Investors Could Be Concerned With Dimed Distribuidora de Medicamentos' (BVMF:PNVL3) Returns On Capital

Second quarter 2022 earnings released

These 4 Measures Indicate That Dimed Distribuidora de Medicamentos (BVMF:PNVL3) Is Using Debt Extensively

Investors Shouldn't Be Too Comfortable With Dimed Distribuidora de Medicamentos' (BVMF:PNVL3) Robust Earnings

First quarter 2022 earnings: Revenues exceed analyst expectations

Price target decreased to R$22.85

No independent directors

Be Wary Of Dimed Distribuidora de Medicamentos (BVMF:PNVL3) And Its Returns On Capital

Full year 2021 earnings: EPS misses analyst expectations

Dimed Distribuidora de Medicamentos (BVMF:PNVL3) Seems To Use Debt Quite Sensibly

Investor sentiment deteriorated over the past week

The Returns On Capital At Dimed Distribuidora de Medicamentos (BVMF:PNVL3) Don't Inspire Confidence

Price target decreased to R$30.20

Third quarter 2021 earnings released

Dimed S.A. Distribuidora de Medicamentos' (BVMF:PNVL3) Stock Retreats 26% But Earnings Haven't Escaped The Attention Of Investors

Investor sentiment deteriorated over the past week

Upcoming dividend of R$0.034 per share

Dimed Distribuidora de Medicamentos (BVMF:PNVL3) Is Reinvesting At Lower Rates Of Return

Dimed S.A. Distribuidora de Medicamentos(BOVESPA:PNVL4) dropped from Brazil Special Tag Along Stock Index

Dimed S.A. Distribuidora de Medicamentos announced that it expects to receive funding from Kinea Private Equity Investimentos S.A.

Dimed S.A. Distribuidora de Medicamentos has completed a Follow-on Equity Offering in the amount of BRL 1.036713 billion.

Prévisions de croissance des bénéfices et des revenus

Prévisions de croissance des analystes

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

Découvrir les entreprises en croissance